These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26604792)

  • 41. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
    Chen Q; Tang L; Liu N; Han F; Guo L; Guo S; Wang J; Liu H; Ye Y; Zhang L; Liu L; Wang P; Li Y; He Q; Yang X; Tang Q; Li Y; Liang Y; Sun X; Xie C; Mo Y; Guo Y; Sun R; Mo H; Cao K; Guo X; Zeng M; Mai H; Ma J
    Cancer Commun (Lond); 2018 Nov; 38(1):66. PubMed ID: 30382933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
    Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J
    BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Changing Role of Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Updated Systemic Review and Network Meta-Analysis.
    Liu M; You W; Song YB; Miao JD; Zhong XB; Cai DK; Xu L; Xie LF; Gao Y
    Front Oncol; 2018; 8():597. PubMed ID: 30619740
    [No Abstract]   [Full Text] [Related]  

  • 47. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
    Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
    Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
    Liao JF; Zhang Q; Du XJ; Lan M; Liu S; Xia YF; Cai XY; Luo W
    Cancer Commun (Lond); 2019 Jun; 39(1):40. PubMed ID: 31248459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials.
    Chen YP; Guo R; Liu N; Liu X; Mao YP; Tang LL; Zhou GQ; Lin AH; Sun Y; Ma J
    J Cancer; 2015; 6(9):883-92. PubMed ID: 26284140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes.
    Xu T; Zhu G; He X; Ying H; Hu C
    Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Huang PY; Cao KJ; Guo X; Mo HY; Guo L; Xiang YQ; Deng MQ; Qiu F; Cao SM; Guo Y; Zhang L; Li NW; Sun R; Chen QY; Luo DH; Hua YJ; Mai HQ; Hong MH
    Oral Oncol; 2012 Oct; 48(10):1038-1044. PubMed ID: 22591726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.
    Tang C; Wu F; Wang R; Lu H; Li G; Liu M; Zhu H; Zhu J; Zhang Y; Hu K
    Am J Cancer Res; 2016; 6(9):2064-2075. PubMed ID: 27725911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials.
    Liang ZG; Zhu XD; Zhou ZR; Qu S; Du YQ; Jiang YM
    Asian Pac J Cancer Prev; 2012; 13(11):5747-52. PubMed ID: 23317250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
    Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
    BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer.
    Zhang D; Wu JR; Duan XJ; Wang KH; Zhao Y; Ni MW; Liu SY; Zhang XM; Zhang B
    Front Pharmacol; 2019; 10():717. PubMed ID: 31333452
    [No Abstract]   [Full Text] [Related]  

  • 56. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment.
    Chen X; Hong Y; Feng J; Ye J; Zheng P; Guan X; You X; Song H
    Chin Med J (Engl); 2014; 127(1):142-9. PubMed ID: 24384440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.